Abstract:
Cet embout inférieur est du type comprenant une plaque ajourée pour permettre le passage d'eau au travers de celle-ci, l'embout possédant des faces latérales (24), et au moins un élément anti-débris (22) disposé sur une face latérale (24) pour bloquer des débris susceptibles de passer entre l'embout inférieur et un autre embout inférieur adjacent. Selon un aspect de l'invention, à l'état libre, le ou chaque élément anti-débris (22) fait saillie en permanence de la face latérale (24) sur laquelle il est disposé, le ou chaque élément anti-débris (22) étant déformable élastiquement de façon à se rétracter en direction de la face latérale (24) en cas d'effort exercé sur l'élément anti-débris (22) en direction de la face latérale (24).
Abstract:
The object of the invention is an dryer in the dryer section (26) of a machine for treating or producing a web (12). This drying section (26) has, amongst other things, a burner assembly (10), wherein this burner assembly (10) is adapted to produce a flame (14) and exhaust gases (18). Either said flame (14) or the exhaust gases (18) or both are in direct contact with the web (12) to be dried. The flame (14) or the exhaust gases (18) or both cover the maximum width of the web (12) to be dried and this at a temperature exceeding 600°C, e.g. above 700°C, e.g. 800°C, preferably 1000°C and more. By applying such a high temperature to the web (12) to be dried, one achieves a large temperature difference, resulting in a better heat transfer. Considering the theoretical equation of heat transfer q x = k x . A x .DT x ,it is evident that because of the large temperature difference, the dimensions of the system can be reduced and/or the efficiency of the drying process can be refined. A further advantage of the higher energy transfer is that the drying process is accelerated and that the web can pass the dryer at high speeds.
Abstract translation:本发明的目的是一种用于处理或生产网(12)的机器的干燥部(26)中的干燥器。 该干燥部分(26)具有燃烧器组件(10),其中该燃烧器组件(10)适于产生火焰(14)和废气(18)。 所述火焰(14)或废气(18)或两者都与要干燥的幅材(12)直接接触。 火焰(14)或废气(18)或两者都覆盖待干燥的幅材(12)的最大宽度,并且在超过600℃的温度下,例如, 高于700℃。 800℃,优选1000℃以上。 通过将这样高的温度施加到要干燥的纤维网(12)上,可以实现较大的温差,导致更好的热传递。 考虑到热传递的理论方程式x x = k x x。 显然,由于温度差大,系统的尺寸可以降低和/或干燥过程的效率可以是 精制。 更高能量转移的另一个优点是加速了干燥过程,并且幅材可以高速地通过干燥器。
Abstract:
The invention concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula (I): wherein n = 2 (i.e. harringtonine) or n = 3(i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97,5%.
Abstract:
The invention concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n = 2 (i.e. harringtonine) or n = 3(i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97,5%.
Abstract:
Derivatives of general formula (I), wherein R is an acyl grouping and R' is a hydrogen atom, a monoester phosphate residue or a substituted carbamate grouping, salt forms thereof and a preparation method therefor, are disclosed. The use of said water-soluble compounds as a drug, as well as for preparing a drug for treating cancer, is also disclosed.
Abstract:
Compound of the general formula (I) in which R' is a hydrogen atom or a radical R and R is an acyl residue. The invention also concerns a process for the preparation of said compound, the use of said compound as a drug and in the preparation of a drug for treating cancer. A pharmaceutical composition comprising said compound is also disclosed.
Abstract:
The present invention concerns harringtonine salts at the solid state exhibiting a protonated nitrogen seen in solid state analysis and having formula (1), comprising solvate, made by reacting a cephalotaxine ester having formula (2), in which R 1 is, but not limited to, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocycloalkyl, and R 2 is, independently, but not limited to H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocycloalkyl, with an acid having general formula AH in a crystallization solvent, wherein the said salt has a water or alkohol solubility ranged approximately from 5 mg/mL to approximately 100 mg/Ml. The invention also related to a process for preparing these salts and their use as chemotherapeutic drugs.
Abstract:
A process for preparing cephalotaxine esters corresponding to the following general formula I which comprises the cephalotaxine backbone: C(R1) (R2) (XH)COO[CTX] wherein CTX represents the cephalotaxine backbone, being optionally substituted and/or dehydrogenated, in which formula I, X is a heteroatom, preferably an oxygen, a sulfur or a nitrogen, R1 and R2, taken separately, may be alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, heterocycloalkyl or aralkyl groups, said groups being optionally interrupted by ester functions, or groups that can form one or more rings or a heterocycle together, consisting in bringing the corresponding cephalotaxine compound, or salts, isomers or tautomeric forms thereof, which is free or which is in the form of a metal alkoxide corresponding to the following general formula CTXOM, wherein CTX represents the cephalotaxine backbone, being optionally substituted and/or dehydrogenated, in which M is a hydrogen atom or a metal atom, into contact with a heterocyclic side chain precursor having both a bifunctional protected (bidentate) and activated (acylating) form of an acid bearing a hydrogenated heteroatom, in the alpha (a) position with respect to the carboxyl group, and corresponding to the following general formula: in which case W is a carbon, sulfur, silicon or bore atom, X, R1 and R2 have respectively the same meaning as above, it being possible for R1 and R2 to form a ring or a heterocycle together, and Y and Z are alkyl or heteroalkyl radicals, or monovalent heteroatoms, which may be identical or different, in an independent manner, or may fuse so as to give a divalent heteroatom, it being possible for the X-W bond to be covalent or ionic.
Abstract:
A process for preparing cephalotaxine esters corresponding to the following general formula I which comprises the cephalotaxine backbone: C(R 1 ) (R 2 ) (XH)COO[CTX] wherein CTX represents the cephalotaxine backbone, being optionally substituted and/or dehydrogenated, in which formula I, X is a heteroatom, preferably an oxygen, a sulfur or a nitrogen, R 1 and R 2 , taken separately, may be alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, heterocycloalkyl or aralkyl groups, said groups being optionally interrupted by ester functions, or groups that can form one or more rings or a heterocycle together, consisting in bringing the corresponding cephalotaxine compound, or salts, isomers or tautomeric forms thereof, which is free or which is in the form of a metal alkoxide corresponding to the following general formula CTXOM, wherein CTX represents the cephalotaxine backbone, being optionally substituted and/or dehydrogenated, in which M is a hydrogen atom or a metal atom, into contact with a heterocyclic side chain precursor having both a bifunctional protected (bidentate) and activated (acylating) form of an acid bearing a hydrogenated heteroatom, in the alpha (α) position with respect to the carboxyl group, and corresponding to the following general formula: in which case W is a carbon, sulfur, silicon or bore atom, X, R 1 and R 2 have respectively the same meaning as above, it being possible for R 1 and R 2 to form a ring or a heterocycle together, and Y and Z are alkyl or heteroalkyl radicals, or monovalent heteroatoms, which may be identical or different, in an independent manner, or may fuse so as to give a divalent heteroatom, it being possible for the X-W bond to be covalent or ionic.
Abstract:
The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising: (a) selecting or identifying an animal suffering from chronic myelogenous leukemia or a related myeloproliferative disorder and showing resistance or intolerance to treatment with STI571; and (b) administering to the animal homoharringtonine. In a preferred embodiment, the animal is a human being.